Abstract
Hodgkin lymphoma (HL) has become one of the most easily curable malignancies in oncology. More than 80% of patients can be cured with risk-adapted treatment that includes chemotherapy and radiotherapy. This progress is mainly due to the development of multi-agent chemotherapy and improved radiation techniques; however, severe, life-threatening treatment-related side effects occur, which include organ toxicity and secondary malignancies. Thus, the treatment approaches must be carefully balanced between optimal disease control and the risk of long-term sequelae. Although this article is meant to provide an overview of the current treatment approaches for patients with HL, in many instances conflicting results from various clinical trials are available, and a personal judgment is inevitable. Here, we focus on evidence from large clinical trials with solid conclusions.
Key Points
-
Based on a large randomized phase III trial, two cycles of ABVD followed by 20 Gy involved-field radiotherapy is recommended as standard of care for early stage favourable Hodgkin lymphoma (HL)
-
Six cycles of escalated BEACOPP followed by 30 Gy radiotherapy for PET-positive residual lymphoma ≥2.5 cm is recommended as standard of care for advanced HL
-
Treatment with 6–8 cycles of ABVD followed by 30 Gy radiotherapy might be an alternative for patients with residual disease >1.5 cm or initial bulky disease
-
Treatment with two cycles of induction chemotherapy followed by high-dose chemotherapy with autologous stem-cell support is recommended for transplant-eligible patients in first relapse
-
In second or higher relapse, individual and palliative treatment is recommended; brentuximab vedotin has shown the most promising activity in this situation
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Santoro, A. et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J. Clin. Oncol. 5, 27–37 (1987).
Aleman, B. M. et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J. Clin. Oncol. 21, 3431–3439 (2003).
Viviani, S. et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N. Engl. J. Med. 365, 203–212 (2011).
Meyer, R. M. et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N. Engl. J. Med. 366, 399–408 (2012).
Horwich, A., Specht, L. & Ashley, S. Survival analysis of patients with clinical stages I or II Hodgkin's disease who have relapsed after initial treatment with radiotherapy alone. Eur. J. Cancer 33, 848–853 (1997).
Fermé, C et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N. Engl. J. Med. 357, 1916–1927 (2007).
Engert, A. et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J. Clin. Oncol. 25, 3495–3502 (2007).
Raemaekers, J. et al. The achievements of the EORTC Lymphoma Group. European Organisation for Research and Treatment of Cancer. Eur. J. Cancer 38 (Suppl. 4), S107–S113 (2002).
Bonadonna, G. et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J. Clin. Oncol. 22, 2835–2841 (2004).
Engert, A. et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N. Engl. J. Med. 363, 640–652 (2010).
Borchmann, P., Diehl, V. & Görgen, H. Dacarbazine is an essential component of ABVD in the treatment of early favourable Hodgkin lymphoma: results of the second interim analysis of the GHSG HD13 trial [abstract]. Haematologica 95 (Suppl. 2), a1146 (2010).
Hutchings, M. et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107, 52–59 (2006).
Gallamini, A. et al. Early interim 2-18fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J. Clin. Oncol. 25, 3746–3752 (2007).
Girinsky, T. et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother. Oncol. 79, 270–277 (2006).
Eich, H. T. et al. Involved-node radiotherapy in early-stage Hodgkin's lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG). Strahlenther. Onkol. 184, 406–410 (2008).
Raemaekers, J. (Presented at the 8th International Symposium on Hodgkin Lymphoma (ISHL), Cologne, 2010).
US National Library of Medicine. ClinicalTrials.gov [online], (2011).
S National Library of Medicine. ClinicalTrials.gov [online], (2009).
Thomas, J., Fermé, C. & Noordijk, E. Results of the EORTC-GELA H9 randomized trials: The H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma [abstract]. J. Clin. Oncol. 23 (Suppl.), a6505 (2005).
Eich, H. T. et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J. Clin. Oncol. 28, 4199–4206 (2010).
US National Library of Medicine. ClinicalTrials.gov [online], (2012).
von Tresckow, B. et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J. Clin. Oncol. 30, 907–913 (2011).
Diehl, V., Mauch, P., Harris, N. L. in Cancer: Principles and practice of oncology, 6th edn, (eds DeVita, V. T. Jr, Hellman, S. & Rosenberg, S.) 2339–2387 (Lippincott Williams & Wilkins, Philadelphia, PA, 2001).
DeVita, V. T. Jr et al. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann. Intern. Med. 92, 587–595 (1980).
Longo, D. L. et al. Twenty years of MOPP therapy for Hodgkin's disease. J. Clin. Oncol. 4, 1295–1306 (1986).
Bonadonna, G., Valagussa, P. & Santoro, A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results. Ann. Intern. Med. 104, 739–746 (1986).
Canellos, G. P. et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N. Engl. J. Med. 327, 1478–1484 (1992).
Duggan, D. B. et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J. Clin. Oncol. 21, 607–614 (2003).
Stefan, D. C. & Stones, D. How much does it cost to treat children with Hodgkin lymphoma in Africa? Leuk. Lymphoma 50, 196–199 (2009).
Canellos, G. P. & Niedzwiecki, D. Long-term follow-up of Hodgkin's disease trial. N. Engl. J. Med. 346, 1417–1418 (2002).
Gobbi, P. G. et al. ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J. Clin. Oncol. 23, 9198–9207 (2005).
Johnson, P. W. et al. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J. Clin. Oncol. 23, 9208–9218 (2005).
Horning, S. J. et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J. Clin. Oncol. 20, 630–637 (2002).
Hoskin, P. J. et al. Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J. Clin. Oncol. 27, 5390–5396 (2009).
Gordon, L. I. et al. A randomized phase III trial of ABVD vs Stanford V ± radiation therapy in locally extensive and advanced stage Hodgkin's lymphoma: An intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496) [abstract]. Blood 116, a415 (2010).
Diehl, V. Dose-escalation study for the treatment of Hodgkin's disease. The German Hodgkin Study Group (GHSG). Ann. Hematol. 66, 139–140 (1993).
Diehl, V. et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N. Engl. J. Med. 348, 2386–2395 (2003).
Engert, A. et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J. Clin. Oncol. 27, 4548–4554 (2009).
Borchmann, P. et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J. Clin. Oncol. 29, 4234–4242 (2011).
US National Library of Medicine. ClinicalTrials.gov [online], (2012).
US National Library of Medicine. ClinicalTrials.gov [online], (2012).
Engert, A. et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet http://dx.doi.org/10.1016/S0140-6736(11)61940-5.
Sieber, M. et al. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. J. Clin. Oncol. 21, 1734–1739 (2003).
Kobe, C. et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112, 3989–3994 (2008).
Federico, M. et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J. Clin. Oncol. 27, 805–811 (2009).
Gianni, A. M. et al. Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin lymphoma: a randomized trial of the Michelangelo, GITIL and IIL cooperative groups [abstract]. J. Clin. Oncol. 26 (Suppl.), a8506 (2008).
Borchmann, P., Diehl, V. & Engert, A. ABVD versus BEACOPP for Hodgkin's lymphoma. N. Engl. J. Med. 365, 1545–1546 (2011).
US National Library of Medicine. ClinicalTrials.gov [online], (2010).
Linch, D. C. et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 341, 1051–1054 (1993).
Schmitz, N. et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 359, 2065–2071 (2002).
Josting, A. et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J. Clin. Oncol. 20, 221–230 (2002).
Josting, A. et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann. Oncol. 13, 1628–1635 (2002).
Moskowitz, C. H. et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 97, 616–623 (2001).
Aparicio, J. et al. ESHAP is an active regimen for relapsing Hodgkin's disease. Ann. Oncol. 10, 593–595 (1999).
Rodriguez, J. et al. ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease. Blood 93, 3632–3636 (1999).
Santoro, A. et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica 92, 35–41 (2007).
Bartlett, N. L. et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann. Oncol. 18, 1071–1079 (2007).
Josting, A. et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann. Oncol. 16, 116–123 (2005).
Josting, A. et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J. Clin. Oncol. 28, 5074–5080 (2010).
Josting, A. et al. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 96, 1280–1286 (2000).
Morschhauser, F. et al. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J. Clin. Oncol. 26, 5980–5987 (2008).
US National Library of Medicine. ClinicalTrials.gov [online], (2012).
US National Library of Medicine. ClinicalTrials.gov [online], (2011).
Younes, A. et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med. 363, 1812–1821 (2010).
Younes, A. et al. Results of a pivotal phase II study of Brentuximab Vedotin (SGN-35) for patients with relapsed or refractory Hodgkin lymphoma [abstract]. J. Clin. Oncol. 29 (Suppl.), a8031 (2012).
DeFrancesco, L. et al. Seattle Genetics rare cancer drug sails through accelerated approval. Nat Biotechnol. 29, 851–852 (2011).
Sureda, A. et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study—a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 97, 310–317 (2012).
Nogova, L., Rudiger, T. & Engert, A. Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma. Hematology Am. Soc. Hematol. Educ Program 266–272 (2006).
Nogova, L. et al. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann. Oncol. 16, 1683–1687 (2005).
Chen, R. C. et al. Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up. J. Clin. Oncol. 28, 136–141 (2010).
Pellegrino, B. et al. Lymphocyte-predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection—a Study of the French Society of Pediatric Oncology. J. Clin. Oncol. 21, 2948–2952 (2003).
Mauz-Körholz, C. et al. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer 110, 179–185 (2007).
Nogová, L. et al. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J. Clin. Oncol. 26, 434–439 (2008).
Schulz, H. et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 111, 109–111 (2008).
Ekstrand, B. C. et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 101, 4285–4289 (2003).
Stark, G. L. et al. Hodgkin's disease in the elderly: a population-based study. Br. J. Haematol. 119, 432–440 (2002).
Proctor, S. J. et al. The role of an all-oral chemotherapy containing lomustine (CCNU) in advanced, fs progressive Hodgkin lymphoma: a patient-friendly palliative option which can result in long-term disease control. Ann. Oncol. 21, 426–428 (2010).
Engert, A. et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. J. Clin. Oncol. 23, 5052–5060 (2005).
Boll, B. et al. Feasibility and efficacy of ABVD in elderly hodgkin lymphoma patients: analysis of two randomized prospective multicenter trials of the German Hodgkin Study Group (HD10 and HD11) [abstract]. Blood 116, a418 (2010).
Ballova, V. et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9 elderly). Ann. Oncol. 16, 124–131 (2005).
Engert, A. et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. J. Clin. Oncol. 23, 5052–5060 (2005).
Boll, B. et al. Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood 118, 6292–6298 (2011).
US National Library of Medicine. ClinicalTrials.gov [online], (2012).
Author information
Authors and Affiliations
Contributions
All authors contributed to researching data for the article, and to writing, editing and reviewing the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Borchmann, P., Eichenauer, D. & Engert, A. State of the art in the treatment of Hodgkin lymphoma. Nat Rev Clin Oncol 9, 450–459 (2012). https://doi.org/10.1038/nrclinonc.2012.91
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2012.91
This article is cited by
-
Cardiovascular screening outcomes in the Dutch survivorship care program for Hodgkin lymphoma survivors
Journal of Cancer Survivorship (2024)
-
Whole body MRI with Diffusion Weighted Imaging versus 18F-fluorodeoxyglucose-PET/CT in the staging of lymphomas
La radiologia medica (2023)
-
Clinical and self-reported markers of reproductive function in female survivors of childhood Hodgkin lymphoma
Journal of Cancer Research and Clinical Oncology (2023)
-
The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity
Scientific Reports (2022)
-
Molecular biology of Hodgkin lymphoma
Leukemia (2021)